New First-line Treatment for EGFR Patients

A new first-line treatment for patients with metastatic non-small cell lung cancer has been approved by the U.S. Food & Drug Administration! The medication, VIZIMPRO® (dacomitinib), is a tyrosine kinase inhibitor (TKI) which targets patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Thank you for your participation in the Bonnie J. Addario Lung Cancer Registry! This month we have exciting news to share with our EGFR patients:

 

A new first-line treatment for patients with metastatic non-small cell lung cancer has been approved by the U.S. Food & Drug Administration! The medication, VIZIMPRO® (dacomitinib), is a tyrosine kinase inhibitor (TKI) which targets patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

 

The approval of VIZIMPRO® is another advance in precision drug development and improving outcomes for patients with mutation-driven lung cancers. Click here to learn more information about this exciting new drug, and view the full prescribing information here.

 

Together we can make a difference as we continue the fight to end lung cancer.

 

Sandra Shaw

Director, Patient Registry

Bonnie J. Addario Lung Cancer Foundation

This email address is being protected from spambots. You need JavaScript enabled to view it.

www.lungcancerregistry.org